Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study
Authors' conclusion
In this post hoc analysis of ICU patients with infections, we found widespread initial use of carbapenems and piperacillin/tazobactam in international ICUs, with the latter being more frequently used.
Study context
- Population
- Critically ill intensive care units (ICU) patients with suspected or confirmed infections, ADRENAL trial and DIANA studyADRENAL n = 3713
- Exposure
- Empirical carbapenems vs piperacillin/tazobactam
- Outcome
- Proportion of patients receiving initial antibiotic treatment with carbapenems and piperacillin/tazobactam
Methodological detailspost hoc analysis, international, two prospectively collected datasets
- Post hoc analysis
- International
- Two prospectively collected datasets
Main finding
As reported in the abstract
Initial antibiotic use
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Mortality · 28 days | Carbapenems (ADRENAL) 23% · Piperacillin/tazobactam (ADRENAL) 24% · Carbapenems (DIANA) 23% · Piperacillin/tazobactam (DIANA) 19% |
| Days alive and out of ICU (DIANA) | Carbapenems (DIANA) median 13 days · Piperacillin/tazobactam (DIANA) median 18 days |
| Hospital LOS (ADRENAL) | Carbapenems (ADRENAL) median 27 days · Piperacillin/tazobactam (ADRENAL) median 21 days |
Original publication
Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study. Acta Anaesthesiol Scand. Published 28 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →